AMBAREEN SALAM: Open Payments
NPI 1053350488 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$702 in 35 payments from 13 companies in 2025. Trend: 2023 $17 · 2024 $412 · 2025 $702
Food & beverage: $702
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 16 | $298 |
| Amgen Inc. | 4 | $81 |
| Cleerly, Inc. | 1 | $59 |
| SANOFI-AVENTIS U.S. LLC | 2 | $40 |
| Exact Sciences Corporation | 2 | $39 |
| Lilly USA, LLC | 2 | $38 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $30 |
| Abbott Laboratories | 1 | $24 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $23 |
| AstraZeneca Pharmaceuticals LP | 1 | $23 |
Products named: Wegovy, Ozempic, OTEZLA, Rybelsus, Cleerly Ischemia, TZIELD, Cologuard Collection Kit, Kerendia.
Industry payments across TX — which companies pay providers there.
